Redpoint Bio

Redpoint Bio Corporation operated as a development-stage biotechnology company, directing its efforts toward the discovery and development of novel taste modulators for several key industries. Initially incorporated in August 1995 as Linguagen Corp., the company was built upon the foundational research of its scientific founder, Robert Margolskee, M.D., Ph.D., a professor at the Mount Sinai School of Medicine whose work centered on the molecular biology of taste signaling pathways. The company held exclusive licenses for key technology patents stemming from Dr. Margolskee's laboratory.

The company's core business focused on creating compounds to enhance desirable tastes and block aversive ones. For the food and beverage sector, Redpoint Bio aimed to identify flavor enhancers that could improve the taste of ingredients, thereby reducing the need for excess sugar and salt. This would enable the creation of healthier and better-tasting consumer products. In the pharmaceutical space, the objective was to develop aversive taste blockers. By suppressing the natural bitterness of many active pharmaceutical ingredients, the company sought to improve patient compliance and expand formulation possibilities for drug manufacturers. The scientific approach was rooted in leveraging discoveries related to the TRPM5 ion channel, which is integral to the perception of sweet, bitter, and umami tastes.

Redpoint Bio's business strategy involved identifying taste-modifying compounds and then developing them for commercial application. The company pursued a Generally Recognized as Safe (GRAS) determination for its taste enhancers, which would allow for wide use across various food products. For its pharmaceutical applications, new drug formulations incorporating its taste blockers would require FDA approval. Over its history, the company underwent several corporate structural changes, including a reverse merger, and became a publicly traded entity on the OTC Bulletin Board under the ticker RPBC. Despite raising capital, including a notable $10.2 million Series A round in 2003 with investors like DuPont Ventures and Cargill Ventures, the company consistently incurred losses and eventually went out of business.

Keywords: taste modulators, biotechnology, food and beverage ingredients, pharmaceutical formulation, flavor enhancers, bitterness blockers, molecular biology, taste signaling, TRPM5 ion channel, Linguagen Corp, Robert Margolskee, aversive taste blockers, GRAS determination, drug development, patient compliance, healthier foods, sugar reduction, salt reduction, OTCBB: RPBC, defunct company